心血管病迎来生物技术药治疗的新时代

Cardiovascular disease is ushering in a new era of biotechnological drugs therapy

近年来,生物技术药研发涌现于心血管病治疗,包括多肽、单克隆抗体、反义寡核苷酸、小干扰核糖核酸、基因编辑疗法和治疗性疫苗。这些信息令人鼓舞,部分药物已经批准临床应用,部分药物仍在进行临床研究,有望成为治疗心血管病的生物技术药,提高心血管病患者治疗的有效性和依从性。

In recent years, biotechnology drugs are emerging in the treatment of cardiovascular disease, include polypeptides, monoclonal antibody(mAb), antisense oligonucleotide(ASO), small interfere ribonucleic acid(siRNA), gene editing therapy, and therapeutic vaccine(TAV). These data are very encouraging, some drugs have been approved for clinical use;however, further studies are needed to introduce those drugs into clinical practice. It is expected to be the new kind of biotechnological drugs for the treatment of cardiovascular diseases, to improve the effectiveness and compliance of treatment in patients with cardiovascular disease.